Transcatheter therapies for secondary mitral regurgitation in advanced heart failure: what are we aiming for?

Andrea Scotti, Andrea Munafò, Alberto Margonato, Cosmo Godino

Research output: Contribution to journalReview articlepeer-review

Abstract

A severe secondary mitral regurgitation (SMR) can be found in a significant portion of patients affected by advanced heart failure (AHF). Conventional therapies (optimal medical therapy, devices, surgery) present restricted clinical efficacy in this stage of the left ventricle disease which is burdened by high mortality and morbidity rates. Although the treatment of choice is represented by heart transplantation (HTx), there is an unmet need related to the limited supply of donor hearts (as opposed to the growing prevalence of AHF) and the low eligibility of highly symptomatic patients. In case of concomitant severe SMR, transcatheter mitral valve therapies (repair and replacement) may play a crucial role in this setting. While a direct prognostic improvement after correction of SMR has yet to be proved, AHF patients can benefit from the following: hemodynamic stabilization, symptomatic relief, normalization of pulmonary arterial pressures, and reduction in hospitalizations for acute heart failure. Obtaining these results may lead to the clinical consequences of reaching the HTx in good enough clinical status (bridge to heart transplantation), becoming eligible for the HTx (bridge to HTx candidacy), and being delisted for clinical improvement (bridge to recovery). Therefore, achieving traditional secondary endpoints in patients with AHF and SMR can translate into significant clinical implications.

Original languageEnglish
JournalHeart Failure Reviews
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • Advanced heart failure
  • Heart transplantation
  • Mitral regurgitation
  • Transcatheter mitral valve repair
  • Transcatheter mitral valve replacement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Transcatheter therapies for secondary mitral regurgitation in advanced heart failure: what are we aiming for?'. Together they form a unique fingerprint.

Cite this